CoJourney

CoJourney CO. is reimagining cell and gene therapy CDMO services globally. Our platform is built on High Purity, High Yield, Time Supply, and Significantly Reduced Costs. We provide process development and clinical and commercial mfg through various platform technologies, including Plasmids, sgRNA & mRNA, AAV / adenovirus, Lentivirus, Retrovirus, and Custom Viral Vectors. We have proprietary high-purity, high-yield, streamlined, and cost-effective processes, and our facilities are compliant with the US FDA, EU EMA, and China NMPA Plasmid, mRNA, and Viral Vector development, manufacturing, and import/export regulations. Plasmids are manufactured in a multi-product cGMP facility that includes multiple upstream suites, downstream suites and a fill-finish suite with an isolator and filler. The facility includes 30L disposable fermenters for plasmid production. Viral Vectors are manufactured in a cGMP viral vector facility that includes multiple upstream cell cultures, upstream viral vector production suites, downstream processing, and fill-finish suites. The facility includes 500L and 2,000L disposable bioreactors for viral vector production. CoJourney’s Process Development labs allow separate, client-specific project rooms with state-of-the-art and large-scale equipment. The analytical development and quality control laboratories provide state-of-the-art analytical equipment focused on analytical development and performing all stages of release testing for plasmids and viral vectors. CoJourney is currently manufacturing AAV-based gene therapies that have been approved for use in global clinical trials: 1) rAAV-based gene therapy for Neurovascular Age-Related Macular Degeneration (wet AMD) in the USA 2) AAV-based gene therapy for Spinal Muscular Atrophy (SMA) in China